Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it is presenting its latest breakthrough antimicrobial products, including the recently United States FDA cleared IV Clear™ at the 2012 FIME International Medical Expo ("FIME") from August 8 to 10 in Miami Beach, Florida.
As a seminar guest speaker, Dr. Val DiTizio, Covalon's Chief Scientific Officer will be discussing why IV Clear is being evaluated by medical institutions that have adopted programs focused on reducing the instances of catheter related bloodstream infections. Clinicians have identified patients who have weak immune systems, sensitive or compromised skin, or who have long-term catheters as groups who can benefit the most from IV Clear. Dr. DiTizio's seminar entitled "A Novel Antimicrobial Clear IV Dressing with Chlorhexidine and Silver" will be presented at 10:00am in room D238 during the FIME Medical Educational Conference on Thursday August 9th at the Miami Beach Convention Center.
Covalon will also be showcasing its latest wound care products such as ColActive® Plus Ag, which is cleared for use in the management of diabetic ulcers and other chronic wounds and SurgiClear™, its unique antimicrobial transparent silicone adhesive surgical dressing to the thousands of international and domestic distributors, group purchasing organizations, hospitals and medical products dealers attending FIME who are looking for advanced products to license and distribute.
"IV Clear is truly a new innovation in the fight against Catheter Related Blood Stream Infections ("CRBSI") and we fully expect IV Clear to be a strong competitor in the United States and International markets," stated Brian Pedlar, Covalon's Chief Executive Officer. "We are looking forward to establishing new distribution relationships at FIME with distributors and hospital buying groups that are interested in sourcing and licensing IV Clear and other Covalon products."